Gut microbial changes in ALS show an uncertain clinical picture
Human studies suggest a relationship between gut microbial changes and ALS, with inconsistent findings and limited evidence that targeting microbes improves outcomes.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review found recurring differences in gut microbes and their metabolic products in people with ALS, but the pattern was not consistent across studies. Some reports linked these differences with disease severity or cognitive difficulties. These associations do not establish whether microbial changes contribute to ALS progression or result from the disease.
The authors identified small samples, differing methods, and limited data tracking changes over time. This abstract-based review summary cannot resolve causality or establish whether any microbiome intervention changes the course of ALS.
What researchers measured
Many studies described fewer bacteria that produce butyrate, alongside changes in other microbes and metabolites. These are biological observations; they do not, by themselves, demonstrate improvements or worsening in symptoms, function, or survival.
The intervention evidence
Some studies found little or no microbial difference, which limits the consistency of the overall pattern. Probiotic trials were described as having limited efficacy, without enough detail in the abstract to quantify a clinical benefit.
The original publication
Microbiota Dysbiosis in Amyotrophic Lateral Sclerosis: A Systematic Review of Human Studies.
Gautam P, Vishwakarma RK, Nath M et al.
Mol Neurobiol · 2025
- PubMed ID
- 41201719
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.